Slingshot Insights

Catalyst

Slingshot members are tracking this event:

NIH study results of off-the-shelf CAR-Ts pose threat to designer CAR-T producers Kite Pharma (KITE) and Juno Therapeutics (JUNO)

Source Link:: http://seekingalpha.com/news/3053086-study-results-may-pressure-valuations-car-t-developers

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies

Importance

High

Medium

Low

Impact on Stocks

KITE

50%

CLLS

50%

JUNO

50%

SIGN ME UP
I want to vote! LOG ME IN
Now!

Additional Information

Additional Relevant Details Off-the-shelf CAR-Ts will be significantly less expensive than designer CAR-Ts offered by KITE and JUNO, which could cost 400K-500K per procedure

http://seekingalpha....

Slingshot Insights Explained

JOIN FOR FREE TODAY

Catalyst Date

Occurred on:

Jan 26, 2016

Related Projects

Don’t see a project related to the catalyst you care about?

Related Keywords Car-t, Car T-cell, Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia, Lymphoma